Ustekinumab in Infliximab-refractory Pediatric UC Ustekinumab in Infliximab-refractory Pediatric UC
This study evaluated the efficacy of ustekinumab following failure of prior biologics in pediatric ulcerative colitis.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 23, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Guidelines: Management of Moderate to Severe Crohn's Disease Guidelines: Management of Moderate to Severe Crohn's Disease
The AGA released guidelines for adult outpatients with moderate to severe Crohn ' s disease, strongly recommending induction and maintenance therapy with anti-TNF-alpha agents or ustekinumab.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - June 16, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
New Phase 3b Psoriatic Arthritis (PsA) Data Show First-in-Class TREMFYA ® (guselkumab) Achieved Robust Joint Symptom Improvement and Complete Skin Clearance in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)
SPRING HOUSE, PENNSYLVANIA, June 2, 2021 – Today the Janssen Pharmaceutical Companies of Johnson & Johnson announced new efficacy and safety data for first-in-class TREMFYA® (guselkumab), including data from the first study evaluating a selective IL-23 inhibitor in adult patients with active PsA, all of whom had demonstrated inadequate response or intolerance to TNFi.1 In the COSMOS Phase 3b study, significantly higher proportions of patients treated with TREMFYA showed joint symptom improvement and complete skin clearance versus placebo at week 24 in this true TNFi-IRa patient population, which is often more diffic...
Source: Johnson and Johnson - June 2, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
SEAVUE: Ustekinumab vs Adalimumab for Crohn's Disease SEAVUE: Ustekinumab vs Adalimumab for Crohn's Disease
For biologic-naive adults with moderate to severe Crohn ' s disease, treatment with either adalimumab or ustekinumab leads to similar outcomes, according to results of the head-to-head SEAVUE trial.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - May 28, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Janssen Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn ’s Disease
SPRING HOUSE, PENNSYLVANIA, May 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced efficacy and safety data for STELARA® (ustekinumab) in Crohn’s disease (CD) and ulcerative colitis (UC),1-4including data from the SEAVUE study, the first head-to-head study of biologic therapies in patients with CD, presented in a Clinical Science Late-Breaking Abstract Plenary session.1 SEAVUE data showed treatment with STELARA demonstrated high rates of clinical remission, corticosteroid-free remission, clinical response and endoscopic response through one year in biologic-naïve patients with mo...
Source: Johnson and Johnson - May 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
VENUS: Ustekinumab Superior to Vedolizumab for Refractory Crohn's VENUS: Ustekinumab Superior to Vedolizumab for Refractory Crohn's
A study directly compares two biologic agents among patients with Crohn ' s disease who failed previous anti-TNF therapy.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - May 21, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
VENUS: Ustekinumab Appears Superior to Vedolizumab for Crohn's VENUS: Ustekinumab Appears Superior to Vedolizumab for Crohn's
A retrospective analysis compares two biologic agents among patients with Crohn ' s disease who failed previous anti-TNF therapy.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - May 21, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
New Phase 3 Data Showed First-in-Class TREMFYA ® (guselkumab) Provided Durable Complete Skin Clearance Through Five Years in Moderate to Severe Plaque Psoriasis (PsO) and Robust Joint Symptom Improvement Through 52 Weeks in Active Psoriatic Arthritis (PsA)
SPRING HOUSE, PENNSYLVANIA, April 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new Phase 3 data which showed TREMFYA® (guselkumab) sustained durable, complete skin clearance rates in a majority of adults with moderate to severe plaque psoriasis (PsO) through five years (252 weeks), a and improved disease activity and axial symptoms in adults with active psoriatic arthritis (PsA) through one year (52 weeks).1,2,3 These data are being presented at the American Academy of Dermatology Virtual Meeting Experience 2021, where Janssen will present a total of 22 abstracts. TREMFYA is t...
Source: Johnson and Johnson - April 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Johnson & Johnson Reports 2021 First-Quarter Results
New Brunswick, N.J. (April 20, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2021. “Johnson & Johnson delivered a strong first quarter performance led by the above market growth of our Pharmaceutical business and continued recovery in Medical Devices,” said Alex Gorsky, Chairman and Chief Executive Officer. “The ability to deliver these results while simultaneously advancing our robust pipeline of life-enhancing medicines, products and solutions during these times is a testament to the strength and resilience of our business and the dedication of the 135,000 employees of Jo...
Source: Johnson and Johnson - April 20, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
New Phase 3 Data Show First-in-Class TREMFYA ® (guselkumab) Achieved Complete Skin Clearance and Favorable Joint Efficacy in Adult Patients with Active Psoriatic Arthritis (PsA) Through Two Years
SPRING HOUSE, PENNSYLVANIA, March 16, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term data from the Phase 3 DISCOVER-2a study showing that the skin clearance, joint symptom relief, and safety of TREMFYA® (guselkumab) previously demonstrated through 24 weeks and one year (Week 52) in adults with active psoriatic arthritis (PsA) continued through two years (Week 112).1,2 These findings also confirmed that the robust efficacy TREMFYA demonstrated in patients at Week 24 on physical function, physical aspects of health-related quality of life, and resolution of enthesitisb and d...
Source: Johnson and Johnson - March 16, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Bimekizumab Superior to Ustekinumab for Plaque Psoriasis
FRIDAY, Feb. 5, 2021 -- For moderate-to-severe plaque psoriasis, bimekizumab is more efficacious than ustekinumab and placebo, according to a study published in the Feb. 6 issue of The Lancet.
Kristian Reich, M.D., from the University Medical... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 5, 2021 Category: Pharmaceuticals Source Type: news
Johnson & Johnson Reports 2020 Fourth-Quarter and Full Year Results
New Brunswick, N.J. (January 26, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2020. “Our notable full year performance reflects the continued confidence from patients, physicians, customers and consumers in our life-enhancing products and medicines, particularly throughout the COVID-19 pandemic,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m incredibly proud of our Johnson & Johnson teams around the world for going above and beyond to meet stakeholder needs. These efforts, and our commitment to families around the world as the largest broad-...
Source: Johnson and Johnson - January 26, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Ustekinumab for Ulcerative Colitis Through 2 Years of Therapy Ustekinumab for Ulcerative Colitis Through 2 Years of Therapy
This long-term extension study assessed the efficacy and safety of one additional year of ustekinumab maintenance treatment in patients originally manifesting moderate-to-severe ulcerative colitis.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 9, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Ustekinumab for Plaque Psoriasis in Pediatric Patients Ustekinumab for Plaque Psoriasis in Pediatric Patients
Ustekinumab is currently approved for the treatment of moderate-to-severe plaque psoriasis in adolescents and adults; is it safe for younger patients?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 12, 2020 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news
Johnson & Johnson Reports 2020 Third-Quarter Results
New Brunswick, N.J. (October 13, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2020. “Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by better-than-expected procedure recovery in Medical Devices, growth in Consumer Health, and continued strength in Pharmaceuticals,” said Alex Gorsky, Chairman and Chief Executive Officer. “I am proud of the relentless passion and Credo-led commitment to patients and customers that our colleagues around the world continue to demonstrate as we boldly fight the COVID-19 pandemic. Our wo...
Source: Johnson and Johnson - October 13, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news
